Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis

被引：0

|

作者：

Papp, Kim ^{[1
]}

Menter, Alan ^{[2
]}

Sofen, Howard ^{[3
]}

Tyring, Stephen ^{[4
]}

Lacour, Jean-Philippe ^{[5
]}

Berner, Beate ^{[6
]}

Bennett, Nathan ^{[7
]}

Aslanyan, Stella ^{[7
]}

Flack, Mary ^{[7
]}

Scholl, Paul ^{[7
]}

机构：

[1] Prob Clin Res, Waterloo, ON, Canada

[2] Baylor Res Inst, Dallas, TX USA

[3] Dermatol Res Associates, Los Angeles, CA USA

[4] Ctr Clin Studies, Houston, TX USA

[5] Hop Archet, Dept Dermatol, Nice, France

[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2144

引用

收藏

页数：2

相关论文

共 24 条

[21] Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
Gooderham, Melinda
Vender, Ronald
Crowley, Jeffrey
Hong, H. Chih-Ho
Feely, Meghan
Garrelts, Alyssa
See, Kyoungah
Konicek, Bruce
Green, Lawrence
DERMATOLOGY AND THERAPY, 2024, 14 (02) : 441 - 451
[22] Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
Melinda Gooderham
Ronald Vender
Jeffrey Crowley
H. Chih-Ho Hong
Meghan Feely
Alyssa Garrelts
Kyoungah See
Bruce Konicek
Lawrence Green
Dermatology and Therapy, 2024, 14 : 441 - 451
[23] Efficacy responses across subgroups of patients with moderate-to-severe plaque psoriasis treated with guselkumab, an anti-interleukin-23p19 monoclonal antibody: results from VOYAGE 1 through 5 years
Thaci, D.
Foley, P.
Puig, L.
Merola, J. F.
Miller, M.
You, Y.
Shen, Y. -K.
Yang, Y. -W.
Blauvelt, A.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E51 - E51
[24] Preliminary clinical safety and efficacy results from an open-label Phase 2 study of STA-5326, an oral IL-12/IL-23 inhibitor, in patients with moderate to severe chronic plaque psoriasis
Gottlieb, A
Cather, J
Hamilton, T
Sherman, M
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB10 - AB10